DMAC (DiaMedica Therapeutics) 5-Year EBITDA Growth Rate: 0.60% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $7.13
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics 5-Year EBITDA Growth Rate?

DiaMedica Therapeutics DMAC -6.68% 31 5-Year EBITDA Growth Rate is 0.60% as of Mar. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

DiaMedica Therapeutics's EBITDA per Share for the three months ended in Mar. 2026 was $-0.20.

During the past 3 years, the average EBITDA Per Share Growth Rate was -11.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 0.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of DiaMedica Therapeutics was 48.80% per year. The lowest was -59.10% per year. And the median was -1.80% per year.

DiaMedica Therapeutics  (NAS:DMAC) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

DiaMedica Therapeutics 5-Year EBITDA Growth Rate Related Terms

DMAC vs PRLD, RCKT, TENX: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, DiaMedica Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DiaMedica Therapeutics 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's 5-Year EBITDA Growth Rate falls into.


DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.60% mean?
DiaMedica Therapeutics (DMAC) has a 5-Year EBITDA Growth Rate of 0.60% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' 5-Year EBITDA Growth Rate too high?
DiaMedica Therapeutics' current 5-Year EBITDA Growth Rate is 0.60%. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' 5-Year EBITDA Growth Rate compare to PRLD and RCKT?
DiaMedica Therapeutics' 5-Year EBITDA Growth Rate of 0.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current 5-Year EBITDA Growth Rate is 0.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current 5-Year EBITDA Growth Rate of 0.60%. The current 5-Year EBITDA Growth Rate is 0.60%. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current 5-Year EBITDA Growth Rate is 0.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.13
Price